Has over 30 years experience developing novel bioconjugation chemistries for both in vivo therapeutics and in vivo and in vitro diagnostics; leads the team at Cell IDx. Dr. Schwartz applied his extensive background in bio-organic chemistry, synthetic organic chemistry, and in vitro and in vivo diagnostics to develop multiplex immunofluorescence technologies.
Dr. Kron received his MD, PhD in Cell Biology from Stanford University and is currently a professor in the Department of Molecular Genetics and Cell Biology at The University of Chicago. Steve has published over a hundred papers and reviews, and is an inventor on multiple patents, several of which have been commercialized.
Gary is the Boston region Managing Partner of Formation Venture Engineering funds, and currently interim CEO of TriBiotica and NonExomics. He serves on numerous boards, including Cell IDx, NeuroDex, and LeviSense. Formation invests in seed stage emerging life science companies with game-changing technologies. He is a co-founder of Sage Science, ActivBiotics, Thrive Bioscience, and Owl Scientific (now ThermoFisher). Mr. Magnant has served on numerous boards, raised substantial venture and angel capital for numerous companies, and guided several of them to successful exits.
Karen is the founder and former CEO of Novus Biologicals, a global e-commerce and life sciences company that develops, licenses, and markets research materials to scientists in academic, corporate, and government laboratories. From 1996 to 2014, Karen bootstrapped Novus from a one-person operation to 120 professionals across four geographies and developed a portfolio of 100,000+ products, growing revenue from $0 to ~$20M by collaborating with leading edge scientists, universities, and companies to produce, license, or OEM antibodies and other reagents to further scientific research. Growth was fueled by a customer-focused culture, great products, not accepting the status quo, and a marketing organization powered by best-in-class digital and eCommerce strategies. In 2014, Bio-Techne (Nasdaq:TECH) acquired Novus Biologicals. From 2014 to 2019, Karen was part of the Leadership team at Bio-Techne, serving as both Head of global marketing and the Antibody Business Unit.
Dr. Walker has more than two decades of experience working in life science tools and diagnostics, having closed more than 45 transactions ranging from large partnerships, licenses, mergers, acquisitions, and divestitures. Cheri is currently the acting Chief Executive Officer of Rhinostics Inc., a Harvard spinout company focused on automating the sample collection and accessioning segment of the laboratory workflow through its unique COVID sample collection device. She has a variety of operating and corporate development roles at bellwether companies including Invitrogen, QIAGEN, Charles River Laboratories, and Abcam in addition to working with many earlier stage companies such as Kailos Genetics. She began her career as a stock analyst at Deutsche Bank, covering life science tools companies. Dr. Walker holds a PhD in Human and Molecular Genetics from Baylor College of Medicine and a BA in Biology from Swarthmore College.